NCT05755087View on ClinicalTrials.gov

Tegavivint for Treating Patients with Relapsed or Refractory Large B-Cell Lymphoma

PHASE1RecruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

March 6, 2023

Primary Completion Date

March 5, 2027

Study Completion Date

March 5, 2027

Conditions
Recurrent Diffuse Large B-Cell Lymphoma Activated B-Cell TypeRecurrent Diffuse Large B-Cell Lymphoma Germinal Center B-Cell TypeRecurrent High Grade B-Cell Lymphoma with MYC and BCL2 or BCL6 RearrangementsRecurrent High Grade B-Cell Lymphoma with MYC, BCL2, and BCL6 RearrangementsRefractory Diffuse Large B-Cell Lymphoma Activated B-Cell TypeRefractory Diffuse Large B-Cell Lymphoma Germinal Center B-Cell TypeRefractory High Grade B-Cell Lymphoma with MYC and BCL2 or BCL6 RearrangementsRefractory High Grade B-Cell Lymphoma with MYC, BCL2, and BCL6 RearrangementsTransformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma
Interventions
PROCEDURE

Biospecimen Collection

Undergo blood sample collection

PROCEDURE

Computed Tomography

Undergo CT

PROCEDURE

Positron Emission Tomography

Undergo PET scan

DRUG

Tegavivint

Given IV

Trial Locations (1)

43210

RECRUITING

Ohio State University Comprehensive Cancer Center, Columbus

All Listed Sponsors
lead

Lapo Alinari

OTHER